From Discovery to Translation: Endogenous Substrates of OAT1 and OAT3 as Clinical Biomarkers for Renal Secretory Function
Clinical Pharmacology & Therapeutics · 2025
DOI: 10.1002/cpt.3719 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Aarzoo Thakur und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington, USA. Hauptthemen laut MEDLINE: Organic Anion Transport Protein 1, Organic Anion Transporters, Sodium-Independent, Kidney. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, NCCIH NIH HHS.
Abstract (Originalsprache)
The recent ICH M12 guidance on Drug Interaction Studies encourages the use of alternate approaches for predicting drug–drug interaction (DDI) potential of new chemical entities. One approach involves the use of endogenous substrates of drug metabolizing enzymes and transporters (DMET) as biomarkers, which can assess the inhibitory potential of new chemical entities towards DMET during Phase 1 clinical studies. Thus, biomarkers could potentially eliminate the need for dedicated DDI studies with exogenous probe substrates. Metabolomics, in conjunction with in vitro and/or in vivo preclinical models or clinical studies, can be used for biomarker discovery. We developed and applied a novel metabolomics‐based DMET biomarker discovery (MDBD) approach to identify and qualify biomarkers of renal organic anion transporter 1 (OAT1) and OAT3. Untargeted metabolomics of pooled plasma and urine samples ( n = 16) from a pharmacokinetic DDI study using the OAT1/3 inhibitor, probenecid, yielded 153 features identified as putative OAT1/3 biomarkers. Subsequently, in vitro transporter uptake assays using processed urine samples confirmed 57 of these features as OAT1 and/or OAT3 substrates. Finally, 23 features were clinically validated as OAT1/3 biomarkers through a detailed pharmacokinetic analysis (0–24 h) of plasma and urine samples ( n = 4). These biomarkers, either alone or as part of a panel, can predict OAT1/3‐mediated DDIs and interindividual variability in the renal secretory clearance of organic anions across different populations, thereby enabling translational utility in clinical settings. The novel MDBD approach can be extended to discover biomarkers of enzymes and other transporters.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington, USA.
- Charles River Laboratories Hungary Kft, Budapest, Hungary.
- Elson S. Floyd College of Medicine, Washington State University Health Sciences Spokane, Spokane, Washington, USA.
- Steve Gleason Institute for Neuroscience, Washington State University Health Sciences Spokane, Spokane, Washington, USA.
ORCID-Profile: Aarzoo Thakur, Katherine D Hart, Mary F Paine, Bhagwat Prasad
Förderung
- NICHD NIH HHS
- NCCIH NIH HHS
Zitieren
APA
Thakur, A., Singh, D. K., Hart, K. D., Kis, E., Gáborik, Z., Denton, T. T., Clarke, J. D., Paine, M. F., & Prasad, B. (2025). From Discovery to Translation: Endogenous Substrates of OAT1 and OAT3 as Clinical Biomarkers for Renal Secretory Function. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3719
Vancouver
Thakur A, Singh DK, Hart KD, Kis E, Gáborik Z, Denton TT, et al. From Discovery to Translation: Endogenous Substrates of OAT1 and OAT3 as Clinical Biomarkers for Renal Secretory Function. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3719
BibTeX
@article{Thakur2025,
author = {Thakur, Aarzoo and Singh, Dilip K and Hart, Katherine D and Kis, Emese and Gáborik, Zsuzsanna and Denton, Travis T and Clarke, John D and Paine, Mary F and Prasad, Bhagwat},
title = {From Discovery to Translation: Endogenous Substrates of OAT1 and OAT3 as Clinical Biomarkers for Renal Secretory Function},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
doi = {10.1002/cpt.3719}
}
EUVIMED